menu ☰
menu ˟

Eylea, nesvacumab combination trials will not continue

27 Nov 2017
Regeneron announced phase 3 development of a combination of Eylea and the angiopoietin2 antibody nesvacumab is not warranted after two phase 2 trials failed to show sufficient differentiation, according to a company press release.The RUBY study, whic...

Click here to view the full article which appeared in Opthalmology

IPH Logo